CAMBRIDGE, England, Jan. 25, 2022 /PRNewswire/ -- LoQus23 Therapeutics Ltd. ('LoQus23'), a biotech discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington's and other triplet repeat diseases, announces the appointment of Dr. Melanie Ivarsson, OBE, as Non-Executive Director of the Board.